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BACKGROUND: The T cell cytokine profile is a key prognostic indicator of post-surgical outcome for colorectal cancer (CRC). Whilst
TH1 (IFN-γ
+) cell-mediated responses generated in CRC are well documented and are associated with improved survival, antigen-
specific TH17 (IL-17A
+) responses have not been similarly measured.
METHODS: We sought to determine the cytokine profile of circulating tumour antigen-(5T4/CEA) specific T cells of 34 CRC patients
to address whether antigen-specific IL-17A responses were detectable and whether these were distinct to IFN-γ responses.
RESULTS: As with IFN-γ-producing T cells, anti-5T4/CEA TH17 responses were detectable predominantly in early stage (TNM I/II) CRC
patients. Moreover, whilst IL-17A was always produced in association with IFN-γ, this release was mainly from two distinct T cell




CONCLUSIONS: Tumour antigen-specific TH17 responses play a beneficial role in preventing post-operative colorectal tumour
recurrence.
British Journal of Cancer (2021) 124:1552–1555; https://doi.org/10.1038/s41416-021-01283-3
BACKGROUND
The adaptive immune system plays a critical role in the control of
colorectal cancer (CRC). Our previous work identified that the
presence of pre-operative circulating TH1 responses specific for
5T4, an oncofoetal antigen not expressed in healthy adult tissue,
has a positive association with post-operative relapse-free survival,1
in keeping with studies demonstrating that tumour infiltration
of TH1-type (IFN-γ-producing) T cells associate with favourable
outcome.2 Unexpectedly, the presence of TH1 responses directed
towards carcinoembryonic antigen (CEA), an auto-antigen
expressed at low levels in normal intestinal epithelium, associated
with poor relapse-free survival in CRC patients.1 Whilst both CEA
and 5T4 are upregulated in the majority of colorectal tumours,
there is a potential that tumour-selective T cell responses impact
clinical outcome differently to auto-antigen T cell responses.3
Since TH1 responses are usually associated with control of
cancer progression, we postulated that CEA-specific IFN-γ-
producing T cells were not the cause of the observed association
with poor survival, but a surrogate marker for skewed tumour-
specific T cell functionality. In particular, tumour-infiltrating TH17
cells have previously been associated with CRC progression.2 IL-
17A itself has been implicated in tumour progression through
STAT3 activation, promoting colonic epithelial cell transformation,
tumour cell proliferation and invasion.4 Contrastingly, the
presence of colorectal tumour-infiltrating TH17 cells was recently
reported to correlate with improved survival,5 implying that IL-17A
has important context and tissue-dependent roles in enacting
pro- or anti-tumour immune mechanisms.6
This current study was designed to identify the presence of
CEA-specific and 5T4-specific IL-17A- and IFN-γ-producing T cells
within the blood of CRC patients and healthy controls and




Blood and colon samples were obtained from 34 patients under-
going colorectal cancer resection or investigative colonoscopy
procedures at the University Hospital of Wales, Cardiff. Patient
characteristics are summarised (Supplementary Table 1). Additional
blood samples were obtained from age-matched healthy donors
(age range 48–62; 5 male, 4 female). All participants gave written,
informed consent personally prior to inclusion. The Wales Research
Ethics Committee granted ethical approval for this study.
Antigens
The CEA protein was split into seventy 20mer peptides and
5T4 split into forty-one 20mers, each overlapping by 10 amino
acids and synthesised to >90% purity (GLBiochem, Shanghai,
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China). Peptides were dissolved in minimal DMSO and incorpo-
rated into peptide pools, used at a final concentration of
1.45 μg/ml/peptide. Phytohaemagglutinin (PHA; Sigma Aldrich)
was used as a positive control.
Peripheral blood mononuclear cell (PBMC) extraction and culture
PBMCs were extracted from whole blood as previously described.1
5 × 105 PBMCs were seeded per well in a 96-well plate in 100 μl R+
media supplemented with 5% human AB serum (Welsh Blood
Service, Pontyclun, UK), 2 mM L-glutamine, 1 mM sodium pyruvate
and 50 μg/ml penicillin/streptomycin (Gibco, Paisley, UK). PBMC
lines were cultured for 14 days in the presence or absence of
peptide pool, supplemented with 10 μl CellKine (purified T cell
growth factors derived from pooled PHA-stimulated T cells;
Helvetica Healthcare, Geneva, Switzerland), on day 3 and fresh
media containing 40 IU/ml IL-2 on days 6 and 9.
FluoroSpot assays
The human IFN-γ/IL-17A FluoroSpot kit (MabTech, Sweden) was
used and performed according to the manufacturer’s instruc-
tions. Duplicate lines of cultured PBMCs were pooled together,
washed and plated at 5 × 105 cells/well with or without the
corresponding peptide pool for direct comparison. FluoroSpot
plates were incubated at 37 °C, 5% CO2 for 48 h. In some
instances, blocking antibodies to MHC class-I (anti-HLA-A/B/B
(W6/32); BioLegend, UK) and MHC class-II (anti-HLA-DR (L243);
anti-HLA-DQ (1A3); BioLegend) were added at a final concentra-
tion of 10 μg/ml, incubated for 30 min before addition of
antigen. Cytokine-producing PBMCs were enumerated using
an automated FluoroSpot reader (CTL, Germany). Dual cytokine-
secreting cells were visualised and enumerated by a compu-
terised overlay. Positive IFN-γ and IL-17A responses were
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Fig. 1 CEA- and 5T4-specific TH1/TH17 responses prevent colorectal tumour recurrence. a The percentage of donors mounting a CEA-
specific IFN-γ response (dark grey), a dual CEA-specific IFN-γ and IL-17A response (light grey), or no positive CEA-specific response (black), as
indicated by results from the IFN-γ/IL-17A FluoroSpot assay. The magnitude of CEA-specific T cell response, normalised to spot-forming cells
(SFC)/105 cultured PBMC, and associated with healthy donor (HD) or early-stage (TNM I/II) or late-stage (TNM III) CRC is shown for IFN-γ (b) and
IL-17A (c). Error bars indicate median with interquartile range. d The percentage of donors mounting a 5T4-specific IFN-γ response (dark grey),
a dual 5T4-specific IFN-γ and IL-17A response (light grey), or no positive 5T4-specific response (black), as indicated by results from the IFN-γ/IL-
17A FluoroSpot assay. The magnitude of 5T4-specific T cell response, normalised to spot-forming cells (SFC)/105 cultured PBMC, and
associated with healthy donor (HD) or early-stage (TNM I/II) or late-stage (TNM III) CRC is shown for IFN-γ (e) and IL-17A (f). Error bars indicate
median with interquartile range. The CEA-specific (g) or 5T4-specific (h) TH1/TH17 response measured in all CRC patients (n= 34) was
associated with relapse-free survival.
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per 1 × 105 cultured PBMC, respectively, and a minimum 2-fold
increase above background.
Intestinal permeability measurements
Electrophysiological resistance and paracellular flux in human
colonic biopsies was measured using an Ussing chamber, as
previously described.7 Readouts of intestinal permeability were
associated with the presence of IFN-γ and IL-17A CEA- and 5T4-
specific T cell responses, with patients differentiated based on the
median magnitude of response generated to each antigen.
Statistical analysis
GraphPad Prism (v.8) was used for all statistical analyses. Dataset
normality was tested using the Shapiro-Wilk test. Significance was
determined using one-way ANOVA with corrections for multiple
comparisons made using the Tukey test; a P-value < 0.05 was
considered significant. For survival analyses using Kaplan–Meier
curves, relapse-free survival was calculated from the date of
surgery to the date of relapse, as determined by follow-up CT scan
and/or endoscopy. Non-relapsing patients were censored at the
time of last follow-up assessment (September 2019). Survival
curves were compared using the log-rank test.
RESULTS
CEA-specific and 5T4-specific IFN-γ, IL-17A and IFN-γ/IL-17A dual-
secreting T cell responses from pre-operative CRC patient and
age-matched healthy donor PBMC were investigated. Culturing
PBMC for 14 days in the presence of a particular cytokine cocktail
was necessary to expand low frequency antigen-specific TH17
responses to detectable levels (Supplementary Fig. 1A). Whilst
TH17 responses were identified, IFN-γ/IL-17A dual secretion from
the same cell was rarely detected; example FluoroSpot well
images and results are shown for CEA and 5T4 (Supplementary
Fig. 1B). CEA- and 5T4-specific TH1 and TH17 cell responses were
readily identifiable amongst healthy donors and cancer patients
(Supplementary Fig. 1C); these responses were predominantly
MHC class II-restricted (Supplementary Fig. 1D). The proportion of
cancer patients mounting detectable CEA-specific IFN-γ T cell
responses diminished in comparison to healthy age-matched
controls (Fig. 1a) and further declined as the tumour became more
advanced (Fig. 1b). No overall change in CEA-specific IL-17A
production was noted between healthy donors and CRC patients
(Fig. 1c).
Similarly, 5T4-specific TH1 responses significantly declined as
the colorectal tumour advanced (HD v III, P= 0.033; I/II v III, P=
0.031; Fig. 1d, e), validating previous findings with 5T41,8 and other
widely-expressed upregulated tumour antigens.9 5T4-specific
TH17 responses were rarely detectable in healthy donors, and
only significantly increased in earlier stage CRC patients (P= 0.036,
Fig. 1f).
The prognostic impact of pre-operative CEA and 5T4-specific
TH1 and TH17 responses was determined by associating responses
with 5-year relapse-free survival. Patients were separated based on
whether they mounted both an IFN-γ and IL-17A response or not
to CEA (Fig. 1g) and 5T4 (Fig. 1h); one patient that mounted an
anti-5T4 IL-17A response only was included as a non-responder.
Although the size of the groups did not allow statistical
significance to be reached, it is clear that in both cases the most
favourable immune profile pre-operatively for prolonged disease-
free survival is the presence of both TH1 and TH17 responses
(Fig. 1g, h).
From this data we conclude that release of IL-17A by CEA-
specific T cells is not responsible for the poorer survival of patients
with IFN-γ-producing CEA (but not 5T4)-specific T cells. Unlike 5T4,
CEA is expressed at low levels in normal epithelium. A higher
magnitude of IFN-γ+ CEA-specific T cell response, i.e. above the
median of all anti-CEA responses tested in patients undergoing
endoscopy (Supplementary Fig. 2A, B), was associated with
decreased electrical resistance in ascending colonic epithelium
(P= 0.037; Supplementary Fig. 2C) and increased paracellular
passage (i.e. leak) of Lucifer yellow probe (P= 0.11; Supplementary
Fig. 2D), implying that the integrity of the epithelial barrier is
subtly compromised in patients with relatively high CEA TH1
response, a finding not replicated when separating responses
based on IL-17A+ CEA responders, nor 5T4 responders from non-
responders. This observation, specific to the right-sided ascending
colonic epithelium, is worthy of further investigation.
DISCUSSION
Mounting pre-operative tumour antigen-specific TH17 and TH1
combined responses appears to be associated with less post-
operative CRC relapse. Despite the relatively small sample size, there
is a clear indication that IL-17A production by tumour antigen-
specific T cells has a positive influence on anti-tumour immunity,
warranting further investigation. In particular, the emergence of 5T4-
specific TH17 response is indicative of early stage CRC and may
provide diagnostic/prognostic information. This study also highlights
the possibility for detrimental clinical outcomes when using IL-17/
TH17-targeted treatments; indeed it has been suggested that clinical
response to anti-PD-1 may be reliant on TH17 responses and
treatment success is compromised by IL-17A blockade.6,10,11
We have previously shown an adverse effects of ex vivo
measured anti-CEA TH1 responses on post-operative CRC patient
outcome.1 In this previous study, we did not measure IL-17A
responses, which require a period of in vitro culture and
expansion. This study, albeit on smaller patient numbers, strongly
suggests that TH17 responses are beneficial when combined with
TH1 responses. It is possible that an IFN-γ-driven chronic, sub-
clinical enteropathy which facilitates tumorigenesis is reversed or
alleviated by IL-17A production.
In conclusion, tumour antigen-specific TH17 responses play a
beneficial role in preventing colorectal tumour recurrence after
surgical resection.
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